Cooley advised the underwriters on Audentes Therapeutics’ $86.3 million shelf-takedown offering of 5,955,151 shares of common stock, which includes 755,151 shares purchased pursuant to the underwriters’…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
